孟鲁司特钠联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的疗效

Efficacy of montelukast sodium combined with budesonide dermotam powder inhalation in the treatment of bronchial asthma

目的观察分析孟鲁司特钠联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床疗效。方法 86例支气管哮喘患者作为研究对象,采用数字随机的方式将患者分为观察组与对照组,各43例。对照组患者给予单纯布地奈德福莫特罗粉吸入剂治疗,观察组患者给予孟鲁司特钠联合布地奈德福莫特罗粉吸入剂治疗。对比两组患者的肺功能指标变化[第一秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)的比值(FEV1/FVC)、呼气峰值流速占预计值的百分比(PEF%预计值)]和莱切斯特咳嗽问卷评分来衡定临床疗效。结果治疗后,两组患者的FEV1、FEV1/FVC、PEF%预计值均较本组治疗前改善,且观察组改善程度优于对照组,差异均具有统计学意义(P<0.05)。治疗前,观察组莱切斯特咳嗽问卷评分为(8.24±1.77)分,对照组为(8.20±1.60)分,比较差异无统计学意义(t=0.1099,P>0.05);治疗后,观察组莱切斯特咳嗽问卷评分为(18.99±1.16)分,对照组为(16.00±1.38)分,观察组高于对照组(t=10.8759,P<0.05)。结论孟鲁司特钠联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘,患者肺部功能显著改善,咳嗽减少,临床疗效良好,值得推广并应用。

Objective To observe the clinical efficacy of montelukast sodium combined with budesonide dermotam powder inhalation in the treatment of bronchial asthma. Methods A total of 86 bronchial asthma patients as study subjects were divided by random number method into observation group and control group, with 43 cases in each group. The control group received budesonide dermotam powder inhalation for treatment, and the observation group received montelukast sodium combined with budesonide dermotam powder inhalation for treatment. Comparison were made on the changes of pulmonary function indicators [ forced expiratory volume in 1 second （FEV1）, FEV1/forced vital capacity （FEV1/FVC） and peak expiratory flow rate percentage of predicted value （PEF%Pred） ] and Leicester cough questionnaire score in two groups. Results After treatment, both groups had better FEV1, FEV1/FVC and PEF%Pred than those of before treatment, and the observation group had better improvement degree than the control group. Their difference had statistical significance （P〈0.05）. Before treatment, the observation group had Leicester cough questionnaire score as （8.24 ± 1.77） points, which was （8.20 ± 1.60） points in the control group, and their difference had statistical significance （t=0.1099, P〉0.05）. After treatment, the observation group had Leicester cough questionnaire score as （18.99 ±1.16） points which was （16.00 ± 1.38） points in the control group. The observation group was higher than the control group （t=10.8759, P〈0.05）. Conclusion Combination of montelukast sodium and budesonide dermotam powder inhalation shows good clinical efficacy in treating bronchial asthma, and it significantly improves pulmonary function of patients and reduces cough. So it is worthy of promotion and application.